Telephone nursing assistance to control Nausea and Vomiting after outpatient Anticancer Chemotherapy

Not Applicable

• Conditions: eoplasms, nausea, vomiting; C23.888.821.712; C23.888.821.937; C04.557.470.200.240

• Registration Number: RBR-6s8qm5
• Lead Sponsor: Instituto do Câncer do Ceará

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2017-09-27
• Last Update Posted: 29 May 2023

Recruitment & Eligibility

• Status: Recruitment completed
• Sex: Not specified
• Target Recruitment: Not specified

Inclusion Criteria

Patients aged 18 years and over, patients receiving moderate chemotherapy and high emetogenic potential (intravenous busulfan, carboplatin, combination of doxorubicin or epirubicin with cyclophosphamide, carmustine, cisplatin, intravenous cyclophosphamide, cytarabine (dose> 200mg / m²);Dacarbazine; Dactinomycin; Doxorubicin; Epirubicin (dose> 90 mg / m², ifosfamide (dose> 2 g / m²), mechlorethamine, melphalan, methotrexate (dose> 250 mg / m²), streptozocin, oxaliplatin)

Exclusion Criteria

Cancer of the gastrointestinal tract; Drug therapy with tramadol; Patients who drink alcohol during the treatment period; Patients undergoing daily chemotherapy regimens, these being given individually or in combination therapy, intravenous or oral routes (busulfan, cyclophosphamide, etoposide, procarbazine)

Study & Design

• Study Type: Intervention
• Study Design: Not specified